Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

FDA Grants Olaparib Breakthrough Designation in mCRPC

Gina Columbus @ginacolumbusonc
Published: Thursday, Jan 28, 2016

Antoine Yver

Antoine Yver

Olaparib (Lynparza) has received an FDA breakthrough therapy designation as a treatment for patients with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer (mCRPC) in those who have received a prior taxane-based chemotherapy and at least either hormonal agent enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Using NGS, the researchers discovered that 16 of 49 (33%) patients had homozygous deletions, deleterious mutations, or both in DNA-repair genes. Fourteen of these 16 (88%) patients (labeled as “biomarker-positive”) responded to olaparib.

Of these 14 patients, 7 harbored BRCA2 mutations, 5 had ATM aberrations, and 2 had ATM mutations with no germline events. Homozygous somatic deletions of BRCA1 or CHEK2 occurred with FANCA deletion in 3 patients, while a somatic frameshift mutation in PALB2 was also detected in a patient with a heterozygous PALB2 deletion. Moreover, biallelic somatic aberrations in histone deacetylase 2 (HDAC2) were identified in 1 patient.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication